Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Dynamic Contrast Enhanced Magnetic Resonance Imaging × Clear all
NCT01996527 2017-04-17

3T MRI Biomarkers of Glioma Treatment Response

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Terminated
7 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡